Interferon   release assay (IGRA) testing in mycobacterium tuberculosis screening prior to anti-tnf treatment: experience across 3 medical specialities

• Published in: Gut Vol. 60; no. Suppl 1; pp. A144 - A145
• Main Authors: Foster, R. A., Shah, M., Hale, M., Grant, W., Abdulrehman, A., Kuet, K. P., Wright, A., Robinson, K., Mark, P., Butler, L., Gawkrodger, D., McAlindon, M., Ridgeway, E., Tattersall, R., Chapman, A., Lobo, A.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.04.2011
• Subjects: Decision making; Immunomodulation; Infectious diseases; Inflammatory bowel diseases; Intestine; Lymphocytes T; Patients; Psoriasis; Risk assessment; Risk factors; Tuberculosis; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors; γ-Interferon

Introduction Anti-tumour necrosis factor (anti-TNF) agents are important treatments for a range of inflammatory conditions but are associated with a fivefold increase risk of tuberculosis (TB). Newer tests based on T cell interferon γ release (IGRA) may aid diagnosis of TB. Aim To assess the impact...